New CAR t cell therapy targets Hard-to-Treat lung cancer
NCT ID NCT07116057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of immunotherapy for people with a specific kind of advanced lung cancer (FRa-positive NSCLC). Researchers take a patient's own immune cells, engineer them to recognize and attack cancer cells, and deliver them directly into the chest cavity. The main goals are to see if this approach is safe and feasible, with only 10 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MOv19-BBz CAR T cells (engineered immune cells targeting a protein called folate receptor-alpha)
What this could lead to
If successful, this could point toward a new treatment option for people with certain lung cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety, not effectiveness. The treatment involves chemotherapy and a temporary chest tube, which carry risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••